PDCD1 and non-small cell lung carcinoma: For instance, the level of local PD-L1 expression, the density of tumor-infiltrating lymphocytes (TILs), and the functional profile of TILs are associated with clinical benefit to PD-1 axis blockers in patients with advanced NSCLC (9–12).